title: Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis.
abstract: BACKGROUND
  Lung cancer is considered a terminal illness with a five-year survival rate of about 16%. Informed decision-making related to the management of a disease requires accurate prognosis of the disease with or without treatment. Despite the significance of disease prognosis in clinical decision-making, systematic assessment of prognosis in patients with lung cancer without treatment has not been performed. We conducted a systematic review and meta-analysis of the natural history of patients with confirmed diagnosis of lung cancer without active treatment, to provide evidence-based recommendations for practitioners on management decisions related to the disease. Specifically, we estimated overall survival when no anticancer therapy is provided.
  
  
  METHODS
  Relevant studies were identified by search of electronic databases and abstract proceedings, review of bibliographies of included articles, and contacting experts in the field. All prospective or retrospective studies assessing prognosis of lung cancer patients without treatment were eligible for inclusion. Data on mortality was extracted from all included studies. Pooled proportion of mortality was calculated as a back-transform of the weighted mean of the transformed proportions using the random-effects model. To perform meta-analysis of median survival, published methods were used to pool the estimates as mean and standard error under the random-effects model. Methodological quality of the studies was examined.
  
  
  RESULTS
  Seven cohort studies (4,418 patients) and 15 randomized controlled trials (1,031 patients) were included in the meta-analysis. All studies assessed mortality without treatment in patients with non-small cell lung cancer (NSCLC). The pooled proportion of mortality without treatment in cohort studies was 0.97 (95% CI: 0.96 to 0.99) and 0.96 in randomized controlled trials (95% CI: 0.94 to 0.98) over median study periods of eight and three years, respectively. When data from cohort and randomized controlled trials were combined, the pooled proportion of mortality was 0.97 (95% CI: 0.96 to 0.98). Test of interaction showed a statistically non-significant difference between subgroups of cohort and randomized controlled trials. The pooled mean survival for patients without anticancer treatment in cohort studies was 11.94 months (95% CI: 10.07 to 13.8) and 5.03 months (95% CI: 4.17 to 5.89) in RCTs. For the combined data (cohort studies and RCTs), the pooled mean survival was 7.15 months (95% CI: 5.87 to 8.42), with a statistically significant difference between the two designs. Overall, the studies were of moderate methodological quality.
  
  
  CONCLUSIONS
  Systematic evaluation of evidence on prognosis of NSCLC without treatment shows that mortality is very high. Untreated lung cancer patients live on average for 7.15 months. Although limited by study design, these findings provide the basis for future trials to determine optimal expected improvement in mortality with innovative treatments.
authors: Center for Evidence Based Medicine and Outcomes Research, Department of Internal Medicine, Morsani College of Medicine, University of South Florida Clinical and Translational Science Institute, 3515 East Fletcher Avenue, MDT 1202, Tampa, FL, 33612, USA.
authors: Hesborn
authors: H
authors: Wao
authors: Rahul
authors: R
authors: Mhaskar
authors: Ambuj
authors: A
authors: Kumar
authors: Branko
authors: B
authors: Miladinovic
authors: Benjamin
authors: B
authors: Djulbegovic
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000401:mortality*; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality*; D016019:Survival Analysis
references: BMC Med. 2004 Jun 09;2:23
references: 15189561
references: Pain. 2004 Jun;109(3):420-431
references: 15157703
references: Eur J Epidemiol. 2010 Sep;25(9):603-5
references: 20652370
references: J Clin Epidemiol. 1997 Jan;50(1):21-9
references: 9048687
references: Oncology. 1992;49(5):321-6
references: 1382255
references: Chest. 1994 Dec;106(6):1797-800
references: 7988203
references: Int J Cancer. 2010 Dec 15;127(12):2893-917
references: 21351269
references: Cancer. 1991 May 15;67(10):2443-7
references: 1849786
references: Chest. 2002 Apr;121(4):1155-8
references: 11948046
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120
references: Cancer. 1989 Apr 1;63(7):1271-8
references: 2465815
references: BMJ. 2005 May 21;330(7501):1179
references: 15894554
references: PLoS Med. 2009 Jul 21;6(7):e1000097
references: 19621072
references: Bull Cancer. 1991;78(4):341-6
references: 1650266
references: BMJ. 2001 Jul 28;323(7306):224-8
references: 11473921
references: Cancer. 1982 Sep 1;50(5):845-9
references: 7093924
references: Ann Intern Med. 2006 Mar 21;144(6):427-37
references: 16549855
references: Lung Cancer. 1999 Apr;24(1):17-24
references: 10403690
references: BMJ. 2009 Feb 23;338:b375
references: 19237405
references: J Clin Oncol. 2007 May 1;25(13):1705-12
references: 17470862
references: J Clin Epidemiol. 2011 Jun;64(6):583-93
references: 21163620
references: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references: 21296855
references: BMC Med Res Methodol. 2005 Apr 20;5:13
references: 15840177
references: J Natl Cancer Inst. 1999 Jan 6;91(1):66-72
references: 9890172
references: J Clin Oncol. 2008 Dec 20;26(36):5988-93
references: 19029419
references: Anticancer Res. 2005 Sep-Oct;25(5):3517-20
references: 16101172
references: Lancet. 1975 Dec 13;2(7946):1161-4
references: 53654
references: J Clin Oncol. 1988 Apr;6(4):633-41
references: 2833577
references: Chest. 1973 Sep;64(3):309-12
references: 4749374
references: Eur J Cancer. 1998 Jun;34(7):1036-44
references: 9849452
references: Lung Cancer. 2003 Mar;39(3):327-30
references: 12609571
references: Br J Cancer. 2000 Aug;83(4):447-53
references: 10945489
references: J Clin Oncol. 2009 May 1;27(13):2253-60
references: 19289623
references: Int J Rehabil Res. 1998 Mar;21(1):29-40
references: 9924664
references: JAMA. 1994 Jul 20;272(3):234-7
references: 8022043
references: J Thorac Oncol. 2008 Jul;3(7):781-92
references: 18594326
references: J Natl Cancer Inst. 1993 May 19;85(10):794-800
references: 8387607
references: BMJ. 2009 Dec 30;339:b4184
references: 20042483
references: BMJ. 2000 Feb 19;320(7233):469-72
references: 10678857
references: J Clin Oncol. 1999 Oct;17(10):3188-94
references: 10506617
references: J Clin Epidemiol. 2006 Dec;59(12):1229-38
references: 17098565
references: J Clin Oncol. 1991 Aug;9(8):1453-61
references: 1649267
references: Semin Oncol. 1985 Mar;12(1 Suppl 2):21-2
references: 3883504
references: J Natl Cancer Inst. 2012 Apr 18;104(8):590-8
references: 22491345